Directors: Domingos Coiteiro | Luísa Albuquerque | Francisco Mascarenhas
NEURO ONCOLOGY SESSION
The treatment of newly diagnosed low grade glioma (LGG) remains one of the most controversial areas in neuro-oncology.
The heterogeneity of these tumors, with various molecular subtypes, concerns with morbidity of available treatments, and the lack of proven global survival benefits of these treatments, have resulted in a lack of consensus regarding the timing and extent of surgery, the timing of radiotherapy and the role of chemotherapy.
Recent developments in the treatment of LGG are practice-changing but further evidence is required regarding risks and benefits of different treatment options.